Portrai Inc

The Solutionist of Pharmaceutical industry Portrai leverages spatial transcriptomics to accelerate the drug discovery and biomarker discovery process. We co-develop the drugs with co-license and provide Platform-as-a-service to pharmaceuticals and biotechs. Radioligand therapy and Antibody-drug conjugate in oncology and brain diseases are therapeutic modalities of interest. AI pathology combined with spatial transcriptomics is our novel approach to make a scalable solution for companion diagnostics. 🟣 PortraiTARGET: Find the target locations that show the best distribution in the tissue and prioritize the target to develop. 🟣 PortraiDRUG & PortraiMIX: Visualize and quantify the drug distribution within the tissue slide to investigate the drug really goes to the target location well. It can be used for drug optimization and drug licensing deals. 🟣 PortraiMOA: Shows the overall changes of RNA expression comparing the spatial transcriptomics data between control and treated group to find out whether the drug works well in that location. 🟣 PortraiTME: Show biomarker distribution in the patient tissues to select the right patients for the drug by integrating H&E slide image and spatial transcriptomics data. It can predict immune/stromal cell proportions and spatial distribution from H&E slide with decent correlation, and even more it could be scaled up to other various biomarkers.